Varenicline in smoking cessation

References

• Fiore MC, Jaén CR, Baker TB et al. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. Executive Summary. Department of Health and Human Services. Public Health Service, MD, USA (2008).
   Google Scholar
• Picciotto MR, Zoli M, Rimondini R et al. Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature391, 173–177 (1998).
   PubMed Web of Science ®Google Scholar
• Pontieri FE, Tanda G, Orzi F, Di Chiara G. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature382, 255–257 (1996).
   PubMed Web of Science ®Google Scholar
• Murray RP, Bailey WC, Daniels K et al.; the Lung Health Study Research Group. Safety of nicotine polacrilex gum used by 3,094 participants in the Lung Health Study. Lung Health Study Research Group. Chest109, 438–445 (1996).
   Google Scholar
• West R, Hajek P, Foulds J, Nilsson F, May S, Meadows A. A comparison of the abuse liability and dependence potential of nicotine patch, gum, spray and inhaler. Psychopharmacology149, 198–202 (2000).
   PubMed Web of Science ®Google Scholar
• Paterson NE, Balfour DJ, Markou A. Chronic bupropion attenuated the anhedonic component of nicotine withdrawal in rats via inhibition of dopamine reuptake in the nucleus accumbens shell. Eur. J. Neurosci.25, 3099–3108 (2007).
   PubMed Web of Science ®Google Scholar
• Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst. Rev.1, CD000031 (2007).
   PubMed Web of Science ®Google Scholar
• Stead LF, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst. Rev.1, CD000146 (2008).
   PubMed Web of Science ®Google Scholar
• Gonzales D, Rennard SI, Nides M et al. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA296, 47–55 (2006).
   PubMed Web of Science ®Google Scholar
• Nakamura M, Oshima A, Fujimoto Y et al. Efficacy and tolerability of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clin. Ther.29, 1040–1056 (2007).
   PubMed Web of Science ®Google Scholar
• Benowitz NL. Nicotine absorption and cardiovascular effects with smokeless tobacco use: comparison with cigarettes and nicotine gum. Clin. Pharmacol. Ther.44, 23–28 (1988).
   PubMed Web of Science ®Google Scholar
• Rose JE, Behm FM, Westman EC, Coleman RE. Arterial nicotine kinetics during cigarette smoking and intravenous nicotine administration: implications for addiction. Drug Alcohol Depend.56, 99–107 (1999).
   PubMed Web of Science ®Google Scholar
• Di Chiara G. Role of dopamine in the behavioural actions of nicotine related to addiction. Eur. J. Pharmacol.393, 295–314 (2000).
   PubMed Web of Science ®Google Scholar
• Nestler EJ. Is there a common molecular pathway for addiction? Nat. Neurosci.8, 1445–1449 (2005).
   PubMed Web of Science ®Google Scholar
• Benowitz NL. Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. Annu. Rev. Pharmacol. Toxicol.49, 57–71 (2009).
   PubMed Web of Science ®Google Scholar
• Laviolette SR, Van der Kooy KD. The neurobiology of nicotine addiction: bridging the gap from molecules to behaviour. Nat. Rev. Neurosci.5, 55–65 (2004).
   PubMed Web of Science ®Google Scholar
• Taly A, Corringer PJ, Guedin D, Lestage P, Changeux JP. Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system. Nat. Rev. Drug Discov.8, 733–750 (2009).
   PubMed Web of Science ®Google Scholar
• Maskos U, Molles BE, Pons S et al. Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors. Nature436, 103–107 (2005).
   PubMed Web of Science ®Google Scholar
• Marubio LM, Gardier AM, Durier S et al. Effects of nicotine in the dopaminergic system of mice lacking the α4 subunit of neuronal nicotinic acetylcholine receptors. Eur. J. Neurosci.17, 1329–1337 (2003).
   PubMed Web of Science ®Google Scholar
• Tapper AR, McKinney SL, Nashmi R et al. Nicotine activation of α4* receptors: sufficient for reward, tolerance and sensitization. Science306, 1029–1032 (2004).
   PubMed Web of Science ®Google Scholar
• Exley R, Clements MA, Hartung H, McIntosh JM, Cragg SJ. α6-containing nicotinic acetylcholine receptors dominate the nicotine control of dopamine neurotransmission in nucleus accumbens. Neuropsychopharmacology33, 2158–2166 (2008).
   PubMedGoogle Scholar
• Gotti C, Clementi F, Fornari A et al. Structural and functional diversity of native brain neuronal nicotinic receptors. Biochem. Pharmacol.78, 703–711 (2009).
   PubMed Web of Science ®Google Scholar
• Coe JW, Brooks PR, Vetelino MG et al. Varenicline: an α4β2 nicotinic receptor partial agonist for smoking cessation. J. Med. Chem.48, 3474–3477 (2005).
   PubMed Web of Science ®Google Scholar
• Cohen C, Bergis OE, Galli F et al. SSR591813, a novel selective and partial alpha4beta2 nicotinic receptor agonist with potential as an aid to smoking cessation. J. Pharmacol. Exp. Ther.306, 407–420 (2003).
   PubMed Web of Science ®Google Scholar
• Rollema H, Coe JW, Chambers LK, Hurst RS, Stahl SM, Williams KE. Rationale, pharmacology and clinical efficacy of partial agonists of α4β2 nACh receptors for smoking cessation. Trends Pharmacol. Sci.28, 316–325 (2007).
   PubMed Web of Science ®Google Scholar
• Coe JW, Rollema H, O’Neill BT. Case history: Chantix™/Champix™ (varenicline tartrate), a nicotinic acetylcholine receptor partial agonist as a smoking cessation aid. Ann. Rep. Med. Chem.44, 71–101 (2009).
   Google Scholar
• Rollema H, Chambers LK, Coe JW et al. Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology52, 985–994 (2007).
   PubMed Web of Science ®Google Scholar
• Rollema H, Shrikhande A, Ward KM et al. Preclinical properties of the α4β2 nAChR partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence. Br. J. Pharmacol.160, 334–345 (2010).
   Google Scholar
• Smith JW, Mogg A, Tafi E et al. Ligands selective for alpha4beta2 but not α3β4 or α7 nicotinic receptors generalise to the nicotine discriminative stimulus in the rat. Psychopharmacology190, 157–170 (2007).
   PubMed Web of Science ®Google Scholar
• O’Connor EC, Parker D, Rollema H, Mead AN. The α4β2 nicotinic acetylcholine-receptor partial agonist varenicline inhibits both nicotine self-administration following repeated dosing and reinstatement of nicotine seeking in rats. Psychopharmacology208, 365–376 (2010).
   PubMed Web of Science ®Google Scholar
• Obach RS, Reed-Hagen AE, Krueger SS et al. Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro. Drug Metab. Dispos.34, 121–130 (2006).
   PubMed Web of Science ®Google Scholar
• Faessel HM, Gibbs MA, Clark DJ, Rohrbacher K, Stolar M, Burstein AH. Multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy smokers. J. Clin. Pharmacol.46, 1439–1448 (2006).
   PubMed Web of Science ®Google Scholar
• Mihalak KB, Carroll FI, Luetje CW. Varenicline is a partial agonist at α4β2 and a full agonist at α7 neuronal nicotinic receptors. Mol. Pharmacol.70, 801–805 (2006).
   PubMed Web of Science ®Google Scholar
• Rollema H, Hajós M, Seymour PA et al. Preclinical pharmacology of the α4β2 nAChR partial agonist varenicline related to effects on reward, mood and cognition. Biochem. Pharmacol.78, 813–824 (2009).
   PubMed Web of Science ®Google Scholar
• Nides M, Oncken C, Gonzales D et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch. Intern. Med.166, 1561–1568 (2006).
   PubMed Web of Science ®Google Scholar
• Oncken C, Gonzales D, Nides M et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch. Intern. Med.166, 1571–1577 (2006).
   PubMed Web of Science ®Google Scholar
• Jorenby DE, Hays JT, Rigotti NA et al. Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA296, 56–63 (2006).
   PubMed Web of Science ®Google Scholar
• Tsai ST, Cho HJ, Cheng HS et al. A randomized, placebo-controlled trial of varenicline, a selective α4β2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clin. Ther.29, 1027–1039 (2007).
   PubMed Web of Science ®Google Scholar
• Wang C, Xiao D, Chan KP et al. Varenicline for smoking cessation: a placebo-controlled, randomized study. Respirology14, 384–392 (2009).
   PubMed Web of Science ®Google Scholar
• Niaura R, Hays JT, Jorenby DE et al. The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trial. Curr. Med. Res. Opin.24, 1931–1941 (2008).
   PubMed Web of Science ®Google Scholar
• Rigotti NA, Pipe A, Benowitz NL, Arteaga C, Garza D, Tonstad S. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation121, 221–229 (2010).
   PubMed Web of Science ®Google Scholar
• Tonstad S, Tonnesen P, Hajek P et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA296, 64–71 (2006).
   PubMed Web of Science ®Google Scholar
• Williams KE, Reeves KR, Billing Jr CB et al. A double-blind study evaluating the long-term safety of varenicline for smoking cessation. Curr. Med. Res. Opin.23, 793–801 (2007).
   PubMed Web of Science ®Google Scholar
• Aubin HJ, Bobak A, Britton JR et al. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax63, 717–724 (2008).
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Rennard S, Hays JT, Ma W, Lee TC. Efficacy and safety of varenicline for smoking cessation in patients with mild to moderate chronic obstructive pulmonary disease. Presented at: CHEST – American College of Chest Physicians. San Diego, CA, USA, 31 October–5 November 2009.
   Google Scholar
• Metcalfe M, Gilljam H, Lund KE, Tonstad S, Fagerström K. A randomized, multicentre, double blind, placebo controlled study evaluating the efficacy of varenicline in cessation of oral tobacco use. Presented at: Meeting of the Society for Research on Nicotine and Tobacco. Baltimore, MD, USA, 24–28 February 2010.
   Google Scholar
• Tsukahara H, Noda K, Saku K. A randomized controlled open comparative trial of varenicline vs nicotine patch in adults smokers. Circ. J.74(4), 771–778 (2010).
   PubMed Web of Science ®Google Scholar
• Eisenberg MJ, Filion KB, Yavin D et al. Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. CMAJ179, 135–144 (2008).
   PubMed Web of Science ®Google Scholar
• Cahill K, Stead L, Lancaster T. A preliminary benefit–risk assessment of varenicline in smoking cessation. Drug Saf.32, 119–135 (2009).
   PubMed Web of Science ®Google Scholar
• Nides M, Glover ED, Reus VI et al. Varenicline versus bupropion SR or placebo for smoking cessation: a pooled analysis. Am. J. Health Behav.32, 664–675 (2008).
   PubMed Web of Science ®Google Scholar
• Fagerström K, Hughes JR. Varenicline in the treatment of tobacco dependence. Neuropsychiatr. Dis. Treat.4, 353–363 (2008).
   Google Scholar
• Hajek P, Tønnesen P, Arteaga C, Russ C, Tonstad S. Varenicline in prevention of relapse to smoking: effect of quit pattern on response to extended treatment. Addiction104, 1597–1602 (2009).
   PubMed Web of Science ®Google Scholar
• Stapleton JA, Watson L, Spirling LI et al. Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction103, 146–154 (2008).
   PubMed Web of Science ®Google Scholar
• Yeh HC, Duncan BB, Schmidt MI, Wang NY, Brancati FL. Smoking, smoking cessation and risk for type 2 diabetes mellitus: a cohort study. Ann. Intern. Med.152, 10–17 (2010).
   PubMed Web of Science ®Google Scholar
• Ferry LH. The power of the press in smokers’ attempts to quit. Br. Med. J.324, 1346–1347 (2002).
   PubMed Web of Science ®Google Scholar
• Gunnell D, Irvine D, Wise L, Davies C, Martin RM. Varenicline and suicidal behavior: a cohort study based on data from the General Practice Research Database. Br. Med. J.339, b3805 (2009).
   PubMed Web of Science ®Google Scholar
• Kasliwal R, Wilton LV, Shakir SA. Safety and drug utilization profile of varenicline as used in general practice in England: interim results from a prescription-event monitoring study. Drug Saf.32, 499–507 (2009).
   PubMed Web of Science ®Google Scholar
• Harrison-Woolrych M. Safety data from New Zealand. Br. Med. J.340, 117–118 (2010).
   Google Scholar
• Moore TJ, Furberg CD. Risk of psychiatric side effects with varenicline. Br. Med. J.339, b4964 (2009).
   PubMed Web of Science ®Google Scholar
• Gunnell D, Irvine D, Wise L, Davies C, Martin RM. Authors’ reply. Br. Med. J.339, b4969 (2009).
   Google Scholar
• Stapleton J. Do the 10 UK suicides among those taking the smoking cessation drug varenicline suggest a causal link? Addiction104, 862–865 (2009).
   Google Scholar
• Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst. Rev. (3) CD006103 (2008).
   Google Scholar
• Tonstad S, Davies S, Flammer M, Russ C, Hughes JR. Psychiatric disorders in ten placebo-controlled clinical trials of varenicline: a pooled analysis. Drug Saf.33, 289–301 (2010).
   PubMed Web of Science ®Google Scholar
• Garza D, Murphy M, Tseng LJ, Riordan H, Chatterjee A. Neuropsychiatric symptoms in smokers quitting with varenicline or placebo: a double-blind, randomized, controlled pilot study. Presented at: European Congress of Psychiatry. Munich, Germany, 27 February–2 March 2010.
   Google Scholar
• McClure JB, Swan GE, Jack L et al. Mood, side-effects and smoking outcomes among persons with and without probably lifetime depression taking varenicline. J. Gen. Intern. Med.24, 563–569 (2009).
   PubMed Web of Science ®Google Scholar
• Rollema H, Guanowsky V, Mineur YS et al. Varenicline has antidepressant-like activity in the forced swim test and augments sertraline’s effect. Eur. J. Pharmacol.605, 114–116 (2009).
   Google Scholar
• Blak BT, Wilson K, Metcalfe M, Maguire A, Hards M. Evaluation of varenicline as an aid to smoking cessation in UK general practice – a THIN database study. Curr. Med. Res. Opin.26(4), 861–870 (2010).
   PubMed Web of Science ®Google Scholar
• Shah SD, Wilken LA, Winkler SR, Swu-Jane L. Systematic review and meta-analysis of combination therapy for smoking cessation. J. Am. Pharm. Assoc.48, 659–665 (2008).
   Google Scholar
• Ebbert JO, Croghan IT, Sood A, Schroeder DR, Hays JT, Hurt RD. Varenicline and bupropion sustained-release combination therapy for smoking cessation. Nic. Tob. Res.11, 572–576 (2009).
   PubMed Web of Science ®Google Scholar